ArticleFrontiers in cellular and infection microbiology2022
Methylene Blue-Mediated Antimicrobial Photodynamic Therapy Against Clinical Isolates of Extensively Drug Resistant Gram-Negative Bacteria Causing Nosocomial Infections in Thailand, An
Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Antimicrobial Strategies in the Era of Resistance: It Is Too Early to Give Up Antibiotic Therapy.International journal of molecular sciences · 2026Review
- Indolicidin-Decorated Photosensitizer for Enhanced Antibacterials and Accelerated Diabetic Wound Healing.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Investigating the Efficacy of Various Photosensitizers and Irradiation Strategies in Antimicrobial Photodynamic Inactivation on Different Types of Microbes.International journal of molecular sciences · 2026Article
- Antimicrobial photodynamic therapy using sodium iron chlorophyllin against drug-resistant Cutibacterium acnes from patients with acne vulgaris.Scientific reports · 2026Article
- Beyond traditional therapies: a narrative overview of antimicrobial photodynamic therapy in combating bacterial and viral infections.Archives of microbiology · 2025Review
- Antimicrobial Photodynamic Activity of the Zn(II) Phthalocyanine RLP068/Cl Versus Antimicrobial-Resistant Priority Pathogens.International journal of molecular sciences · 2025Article
- Zirconium Dental Implants as Potential Optical Waveguides in Photodynamic Inactivation of Bacterial Biofilms-A Pilot Study.Microorganisms · 2025Article
- Article
- Use of Antimicrobial Photodynamic Therapy to Inactivate Multidrug-ResistantPharmaceutics · 2024Article
- In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells Death.International journal of molecular sciences · 2024Article
- Deciphering Chemical Rules for Drug Penetration into Strongyloides.Pharmaceutics · 2024Article
- Photodynamic therapy on mRNA levels in bacteria.Lasers in medical science · 2024Review
- In Vitro Antimicrobial Photodynamic Therapy forPharmaceutics · 2024Article
- Article
- Antimicrobial Resistance: Is There a 'Light' at the End of the Tunnel?Antibiotics (Basel, Switzerland) · 2023Review
- Managing Corneal Infections: Out with the old, in with the new?Antibiotics (Basel, Switzerland) · 2023Review
- Photodynamic Therapy, Probiotics, Acetic Acid, and Essential Oil in the Treatment of Chronic Wounds Infected withPharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Purpose: Some multidrug-resistant gram-negative bacteria as a global threat have been recently prioritized for research and development of new treatments. We studied the efficacy of methylene blue-mediated antimicrobial photodynamic therapy (MB-aPDT) for the reduction of extensively drug-resistant Method: Two isolates of each selected bacterium were collected, XDR-AB1 and AB2, XDR- PS1 and PS2, and MDR-KP1 and KP2. Three triplicate experiments using various MB concentrations alone, various red light fluences alone, as well as the selected non-toxic doses of MB and fluences of red light combined as MB-aPDT were applied on each selected isolate. The colonies were counted [colony forming units (CFU)/ml]. Estimation of the lethal treatment dose defined as reduction of > 2 log Result: There were generally negligible changes in the viable counts of the bacterial suspensions treated with all the MB concentrations (p > 0.05). In the second experiment with the only red light treatments, at fluences higher than 2 J/cm, reduction trend in viable counts across all the isolates was observed. Only for MDR-KP1, however, the lethal dose was achieved with the highest fluence of red light (80 J/cm). With the concentration of MB, 50 and 150 mg/L in the third experiment (MB-aPDT), the greater bacterial reduction was observed in all clinical isolates leading to their lethal viable cell reduction when escalating the light fluence to 80 J/cm. Conclusions: MB-aPDT evidently killed the selected XDR and MDR-gram negative bacteria. In highly drug-resistant crisis era, MB-aPDT could be a promising option, particularly for local infections and infection complicating chronic wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.